This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

David Einhorn Causes athenaHealth Rout: Highlights from Ira Sohn 2014

Updated from 9:57 a.m ET with analyst comments and afternoon athenaHealth share prices.

NEW YORK (TheStreet) - When David Einhorn speaks, the markets listen. On Monday, the hedge fund manager did not disappoint.

Speaking last at an conference featuring all-star hedge fund managers such as Paul Tudor Jones, Bill Ackman and Larry Robbins, Einhorn, the Greenlight Capital Management founder disclosed he had shorted shares of athenaHealth (ATHN - Get Report) as part of a basket of technology stocks he believes are indicative of a bubble.

Einhorn's presentation of his athenaHealth short sent shares in the high-flying health business services company tumbling over 10%. The hedge funder's scathing review of an April 23 upgrade of the company by Morgan Stanley analysts titled "All about the TAM," meanwhile, may cause many investors to speculate upon what other stocks Einhorn has in his bubble basket.

Must Read: DoubleLine's Gundlach Bleak on Home Ownership

While Morgan Stanley valued athenaHealth at $192 a share, Einhorn walked attendees at the 19th annual Ira Sohn Conference presented with BloombergLINK through his analysis of why he believed that valuation to be off the mark.

If Morgan Stanley valued athenaHealth's inpatient business at $72 a share and the company's ambulatory business at $120 a share, Einhorn said he believes athenaHealth is worth about $50 a share under ordinary circumstances and $14 a share in a bear case valuation.

Einhorn questioned Morgan Stanley's forecasts of athenaHealth's profit margins, for instance, their estimate that earnings before interest and tax (EBIT) margins would reach 30% by 2030. Morgan Stanley's margin assumptions may be comparable to a cloud software business, however, Einhorn characterized athenaHealth more as a business process outsourcing company in the health care sector and said he believed EBIT margins will be closer to 15%.

"We believe that these assumptions are quite aggressive and likely to prove too optimistic," Einhorn said of Morgan Stanley's 2030 forecast. He also characterized Morgan Stanley's valuation as an attempt to justify the company's stock price.

Given Morgan Stanley's 30% margin forecast, a 5% perpetual growth rate and a 10.8% weighted average cost of capital, Einhorn's far-lower number significantly impacted his discounted cash flow valuation of athenaHealth.

Meanwhile, Einhorn said Morgan Stanley may have overvalued the company's inpatient business. If Morgan Stanley valued the business at $72 a share, Einhorn said he believes that valuation should be closer to $7 a share.

Morgan Stanley had its defenders. At least six wall street research firms re-iterated the equivalent of 'buy' ratings on athenaHealth's stock on Tuesday, with Stephens Inc., Leerink Partners, Piper Jaffray, and Sterne Agee re-iterating price targets higher than that of Morgan Stanley.

"While value is in the eye of the beholder, we respectfully disagree with the assessment that ATHN shares are overvalued," Sterne Agee wrote. Analysts at the firm said athenaHealth continues to win physician accounts and will continue to generate 25%-to-30% revenue growth year-over-year.

Leerink analysts, responding to one part of Einhorn's presentation, said athenaHealth may be able to continue winning community hospitals even if competitor Epic dominates larger accounts such as research university medical centers. "[We] do believe athenaHealth can compete in the smaller community hospital space.

None of the bullish Wall Street notes on Tuesday helped athenaHealth, however. Shares opened down down about 10% and were trading off by over 14% in late afternoon trading at $108.39

Paul Tudor Jones Feeling GILT'y on Rates

Paul Tudor Jones, the head of macro-hedge fund Tudor Investment Corporation, made a rare public appearance at the Ira Sohn Conference, which is a charitable event to support cancer research. Jones, a founder of the Robin Hood Foundation, applauded the aims of the conference and presented an often funny explanation of why it's been such a hard time for macro-traders to make money.

"It has gotten very difficult when you make a living depending on price movement," Jones said.

Macro funds like Tudor are patiently waiting a rise in interest rates around the world as Central Banks bring short-term rates from the zero bound, returning interest rate volatility, spreads, and carry trades to markets. Friday, Jones said, should have been the day macro traders have awaited.

A non-farm payroll report that included 288,000 new jobs and a fall in the U.S. unemployment rate to 6.3%, in addition to strong economic reports around the world should have caused bond yields to surge as investors prepared for looming rate hikes in the U.S., Europe and Asia, Jones said. Instead, bond prices closed the day higher.

"It just goes to show that what is obvious is obviously wrong," Jones said.

He believes macro-traders will remain in the doldrums through the second quarter, but that forecast of a rate hike by the Bank of England at the end of 2014 will cause trading activity ahead of that move by July. "Nothing is going to happen in fixed income, it is broadly imbalanced, for the first seven months of this year," Jones said. U.K GILT's will be a decent sale in July, Jones concluded.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
FMCC $1.55 0.00%
FNMA $1.70 0.00%
ATHN $133.30 0.00%
LBTYA $37.73 0.00%
NFLX $90.03 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs